Myomo, Inc. (MYO) News
Filter MYO News Items
MYO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MYO News Highlights
- For MYO, its 30 day story count is now at 2.
- Over the past 8 days, the trend for MYO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TOP are the most mentioned tickers in articles about MYO.
Latest MYO News From Around the Web
Below are the latest news stories about MYOMO INC that investors may wish to consider to help them evaluate MYO as an investment opportunity.
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
7 Stock Winners That Are Up 1,000% or More in 2023Could any or all of these seven stocks up 1000% this year go on another hot run during 2024? |
Top Penny Stocks for Q4 2023Top penny stocks this month include Myomo Inc., Expion360 Inc., and Akebia Therapeutics Inc., all of which have more than tripled in value this last year. |
3 Hot Penny Stocks to Buy in Q4 for Promising PotentialPenny stocks are typically companies that are trading below $5 per share. |
Myomo, Inc. (AMEX:MYO) Q3 2023 Earnings Call TranscriptMyomo, Inc. (AMEX:MYO) Q3 2023 Earnings Call Transcript November 7, 2023 Myomo, Inc. beats earnings expectations. Reported EPS is $-0.05753, expectations were $-0.08. Operator: Hello, and welcome to the Myomo Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to […] |
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and AuthorizationsBOSTON, November 07, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2023. |
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public MeetingBOSTON, November 06, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) posted a proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rate for the MyoPro® to be discussed at CMS’ bi-annual Healthcare Common |
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit CategoryBOSTON, November 02, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rule classifying the MyoPro under the brace benefit category. Braces are paid on a lump sum basis under the Social Security Act. The finalization of MyoPro’s classification as |
Myomo to Report Third Quarter Financial Results on November 7, 2023BOSTON, October 31, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023. |
Myomo Announces Closing of $4.4 Million Public OfferingBOSTON, August 29, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximat |